A Phase II Randomized, Placebo Controlled Clinical Trial to Study the Efficacy and Safety of Bicalutamide With or Without Deforolimus in Men With Asymptomatic, Metastatic Castrate-Resistant Prostate Cancer.
Phase of Trial: Phase II
Latest Information Update: 10 Sep 2016
At a glance
- Drugs Ridaforolimus (Primary) ; Bicalutamide
- Indications Prostate cancer
- Focus Adverse reactions; Therapeutic Use
- Sponsors Merck Sharp & Dohme
- 10 Jun 2017 Biomarkers information updated
- 09 Nov 2012 Planned number of patients changed from 156 to 180.
- 11 Jun 2010 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.